UA76417C2 - Pharmaceutical composition comprising immediate release phase and sustained release phase of paracetamol - Google Patents
Pharmaceutical composition comprising immediate release phase and sustained release phase of paracetamol Download PDFInfo
- Publication number
- UA76417C2 UA76417C2 UA2002108076A UA2002108076A UA76417C2 UA 76417 C2 UA76417 C2 UA 76417C2 UA 2002108076 A UA2002108076 A UA 2002108076A UA 2002108076 A UA2002108076 A UA 2002108076A UA 76417 C2 UA76417 C2 UA 76417C2
- Authority
- UA
- Ukraine
- Prior art keywords
- paracetamol
- composition according
- minutes
- released
- immediate
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 93
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 92
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 title abstract description 59
- 238000013268 sustained release Methods 0.000 title abstract description 33
- 239000012730 sustained-release form Substances 0.000 title abstract description 33
- 238000004090 dissolution Methods 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims description 75
- 229920000642 polymer Polymers 0.000 claims description 14
- 230000009471 action Effects 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 229920003169 water-soluble polymer Polymers 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims 7
- 230000009474 immediate action Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 53
- 208000002193 Pain Diseases 0.000 description 29
- 230000036407 pain Effects 0.000 description 25
- 238000009472 formulation Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 9
- 230000036592 analgesia Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 239000000945 filler Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- -1 for example Polymers 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UAYRCOSFOXJQAB-UHFFFAOYSA-N 1-(2-amino-5-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(O)=CC=C1N UAYRCOSFOXJQAB-UHFFFAOYSA-N 0.000 description 1
- 208000032529 Accidental overdose Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022523 Intentional overdose Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000604 anti-edema agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Confectionery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0009522.4A GB0009522D0 (en) | 2000-04-19 | 2000-04-19 | Composition |
PCT/EP2001/004302 WO2001080834A1 (en) | 2000-04-19 | 2001-04-12 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
UA76417C2 true UA76417C2 (en) | 2006-08-15 |
Family
ID=9890126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2002108076A UA76417C2 (en) | 2000-04-19 | 2001-12-04 | Pharmaceutical composition comprising immediate release phase and sustained release phase of paracetamol |
Country Status (25)
Country | Link |
---|---|
US (2) | US7943170B2 (ko) |
EP (1) | EP1274402B1 (ko) |
JP (1) | JP2003531165A (ko) |
KR (1) | KR100845660B1 (ko) |
CN (1) | CN100335046C (ko) |
AT (1) | ATE438388T1 (ko) |
AU (2) | AU2001260212C1 (ko) |
BR (1) | BR0110129A (ko) |
CA (1) | CA2406373C (ko) |
CO (1) | CO5280073A1 (ko) |
CY (1) | CY1109483T1 (ko) |
CZ (1) | CZ303275B6 (ko) |
DE (1) | DE60139462D1 (ko) |
DK (1) | DK1274402T3 (ko) |
EA (1) | EA006103B1 (ko) |
ES (1) | ES2329971T3 (ko) |
GB (1) | GB0009522D0 (ko) |
HK (1) | HK1053601A1 (ko) |
HU (1) | HU230033B1 (ko) |
MX (1) | MXPA02010347A (ko) |
NZ (1) | NZ521799A (ko) |
TW (1) | TWI282286B (ko) |
UA (1) | UA76417C2 (ko) |
WO (1) | WO2001080834A1 (ko) |
ZA (1) | ZA200208084B (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
US20040186180A1 (en) * | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
CN100348974C (zh) * | 2003-09-30 | 2007-11-14 | 北京东方凯恩医药科技有限公司 | 一种药物组合物的检测方法 |
US20050095299A1 (en) * | 2003-10-30 | 2005-05-05 | Wynn David W. | Controlled release analgesic suspensions |
JP5269595B2 (ja) | 2005-09-09 | 2013-08-21 | アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー | 1日1回投与用トラゾドン組成物 |
US20080057122A1 (en) * | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
ES2541809T3 (es) * | 2007-10-16 | 2015-07-24 | Paladin Labs Inc. | Composición bicapa para la liberación sostenida de acetaminofeno y tramadol |
EP2219612A4 (en) | 2007-12-17 | 2013-10-30 | Paladin Labs Inc | CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
EP2262484B1 (en) | 2008-03-11 | 2013-01-23 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
EP2367541B1 (en) | 2008-12-16 | 2014-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
CA2752233C (en) * | 2009-02-13 | 2017-01-03 | Romark Laboratories L.C. | Controlled release pharmaceutical formulations of nitazoxanide |
US20110052685A1 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
SG194605A1 (en) * | 2011-05-06 | 2013-12-30 | Glaxosmithkline Llc | Sustained release paracetamol formulations |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US20140206740A1 (en) * | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
EA028481B1 (ru) * | 2012-10-18 | 2017-11-30 | Эббви Инк. | Препараты производных пиримидиндиона |
WO2016042570A1 (en) * | 2014-09-16 | 2016-03-24 | Suresh Pareek | Extended release formulation of acetaminophen |
ES2884973T3 (es) | 2016-03-09 | 2021-12-13 | Nls Pharmaceutics Ag | Comprimido multicapa de mazindol de IR/SR y su utilización para el tratamiento del trastorno por déficit de atención/hiperactividad (ADHD) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2058562B (en) * | 1979-09-14 | 1983-11-30 | Beecham Group Ltd | Pharmaceutical compositions containing paracetamol and ascorbic acid |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
EP0418596A3 (en) * | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
US5900425A (en) * | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
BE1011045A3 (fr) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
FR2766708B1 (fr) | 1997-07-30 | 2000-05-05 | Galenix Dev | Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention |
US5945123A (en) * | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
US6254891B1 (en) | 1998-09-03 | 2001-07-03 | Ascent Pediatrics, Inc. | Extended release acetaminophen |
US6126967A (en) | 1998-09-03 | 2000-10-03 | Ascent Pediatrics | Extended release acetaminophen particles |
GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
US7897172B2 (en) * | 2004-05-18 | 2011-03-01 | L. Perrigo Company | Tablets exhibiting reduced drug release variability |
-
2000
- 2000-04-19 GB GBGB0009522.4A patent/GB0009522D0/en not_active Ceased
-
2001
- 2001-04-12 AT AT01933832T patent/ATE438388T1/de not_active IP Right Cessation
- 2001-04-12 AU AU2001260212A patent/AU2001260212C1/en not_active Expired
- 2001-04-12 JP JP2001577934A patent/JP2003531165A/ja active Pending
- 2001-04-12 DE DE60139462T patent/DE60139462D1/de not_active Expired - Lifetime
- 2001-04-12 MX MXPA02010347A patent/MXPA02010347A/es active IP Right Grant
- 2001-04-12 ES ES01933832T patent/ES2329971T3/es not_active Expired - Lifetime
- 2001-04-12 HU HU0300698A patent/HU230033B1/hu not_active IP Right Cessation
- 2001-04-12 CZ CZ20023470A patent/CZ303275B6/cs not_active IP Right Cessation
- 2001-04-12 CA CA2406373A patent/CA2406373C/en not_active Expired - Fee Related
- 2001-04-12 EA EA200200954A patent/EA006103B1/ru not_active IP Right Cessation
- 2001-04-12 CN CNB018084036A patent/CN100335046C/zh not_active Expired - Lifetime
- 2001-04-12 KR KR1020027014009A patent/KR100845660B1/ko active IP Right Grant
- 2001-04-12 EP EP01933832A patent/EP1274402B1/en not_active Expired - Lifetime
- 2001-04-12 BR BR0110129-3A patent/BR0110129A/pt active Search and Examination
- 2001-04-12 US US10/257,077 patent/US7943170B2/en not_active Expired - Fee Related
- 2001-04-12 NZ NZ521799A patent/NZ521799A/xx not_active IP Right Cessation
- 2001-04-12 AU AU6021201A patent/AU6021201A/xx active Pending
- 2001-04-12 DK DK01933832T patent/DK1274402T3/da active
- 2001-04-12 WO PCT/EP2001/004302 patent/WO2001080834A1/en active IP Right Grant
- 2001-04-17 CO CO01029583A patent/CO5280073A1/es not_active Application Discontinuation
- 2001-04-18 TW TW090109284A patent/TWI282286B/zh not_active IP Right Cessation
- 2001-12-04 UA UA2002108076A patent/UA76417C2/uk unknown
-
2002
- 2002-10-08 ZA ZA200208084A patent/ZA200208084B/en unknown
-
2003
- 2003-06-16 HK HK03104302.2A patent/HK1053601A1/xx not_active IP Right Cessation
-
2009
- 2009-10-13 CY CY20091101055T patent/CY1109483T1/el unknown
-
2011
- 2011-03-29 US US13/074,944 patent/US20110177168A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA76417C2 (en) | Pharmaceutical composition comprising immediate release phase and sustained release phase of paracetamol | |
US5200193A (en) | Pharmaceutical sustained release matrix and process | |
EP0312581B1 (en) | Pharmaceutical sustained release matrix and process | |
US5004613A (en) | Oral sustained release pharmaceutical formulation and process | |
AU2001260212A1 (en) | Composition | |
AU2016208417A1 (en) | Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate | |
NL8302842A (nl) | Naproxeen en naproxeen natrium tabletten met een geregelde afgifte. | |
RU2153337C2 (ru) | Таблетка парацетамола и домперидона с пленочным покрытием | |
CN100389751C (zh) | 含扑热息痛的吞咽片剂 | |
EP1392271B1 (en) | Swallow tablet comprising paracetamol | |
KR960006061B1 (ko) | 약제학적 서방성 매트릭스 및 제조방법 | |
RU2174836C1 (ru) | Фармацевтическая композиция, обладающая анальгезирующим действием | |
JPS6360926A (ja) | 感冒薬 | |
JPH047323B2 (ko) | ||
MXPA97006492A (en) | Use of isosorb 5-mononitrate |